 | | Vol. 10.25 – 28 June, 2022 |
| |
|
|
| Using a CRISPR-based screen for negative regulators of memory T cell generation in vivo, the authors identified multiple components of the mammalian canonical BRG1/BRM-associated factor (cBAF).
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported integrated molecular analyses of tumor samples from 358 patients with hepatocellular carcinoma enrolled in the GO30140 Phase Ib or IMbrave150 Phase III trial and treated with atezolizumab combined with bevacizumab, atezolizumab alone, or sorafenib.
[Nature Medicine] |
|
|
|
| In vivo CRISPR screens in murine and human tumor models demonstrated that perturbation of the INO80 and BAF chromatin remodeling complexes improved T cell persistence in tumors.
[Cancer Cell] |
|
|
|
| Investigators used single-cell cellular indexing of transcriptomes and epitopes by sequencing to reveal the immunotranscriptome of surgically resected epileptic lesion tissues.
[Nature Neuroscience] |
|
|
|
| The authors curated more than 700 immune checkpoint inhibitor (ICI)-treated patient samples with clinical outcomes and transcriptomic data, and observed that NetBio-based predictions accurately predicted ICI treatment responses in three different cancer types — melanoma, gastric cancer, and bladder cancer.
[Nature Communications] |
|
|
|
| Investigators characterized the peripheral blood and intestinal tissue of Crohn’s disease patients with flow and mass cytometry and revealed a strong increase of Tc17 cells in active disease, mainly due to induction of conventional T cells.
[Nature Communications] |
|
|
|
| Researchers characterized IgE epitopes of Art v 1–sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy.
[Journal of Allergy and Clinical Immunology] |
|
|
|
| The authors investigated the association of FAT atypical cadherin 1 (FAT1) mutations with immune checkpoint inhibitor response and outcome.
[npj Precision Oncology] |
|
|
|
| Scientists showed the alterations in the transcriptional landscape of hematopoietic cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow and revealed that G-CSF-induced myeloid-biased differentiation initiated from the stage of lymphoid-primed multipotent progenitors.
[Cell Discovery] |
|
|
|
| Researchers established whether granulocyte colony-stimulating factor treatment (G-CSF) negatively influenced T cell phenotype and to ascertain whether previous exposure of T cells to G-CSF was deleterious for anti-B-cell maturation antigen (BCMA) CAR-T cells.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| The authors investigated the correlation between the expression of sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) and programmed death-ligand 1 (PD-L1) in nasopharyngeal carcinoma patients.
[Scientific Reports] |
|
|
|
| Netrin-4 (NTN4) was significantly positively related to infiltration of CD8+ T cells, macrophages, and neutrophils, whereas significantly negatively related to B cells and tumor purity.
[Scientific Reports] |
|
|
|
|
| Scientists review the different methodologies for developing a more holistic patient-derived tumor organoid platform and for modeling the native immune tumor microenvironment.
[Trends in Cancer] |
|
|
|
| The authors summarize and discuss the latest research and advancements on small extracellular vesicle (sEV) programmed death protein 1 ligand (PD-L1), including the biogenesis and secretion mechanisms, isolation and detection strategies, as well as the biological functions of sEV PD-L1.
[npj Precision Oncology] |
|
|
|
| There is evidence to suggest that autoimmune diseases can be suppressed by anti-inflammatory bioactive lipids LXA4, resolvins, protecting, and maresins.
[European Journal of Clinical Nutrition] |
|
|
|
|
| Xenikos B.V. announced the enrolment of the first patient in a global pivotal Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant.
[Xenikos B.V.] |
|
|
|
| Mustang Bio, Inc. announced that the US FDA has granted Orphan Drug Designation to MB-106, Mustang’s CD20-targeted, autologous CAR T cell therapy for the treatment of Waldenstrom macroglobulinemia, a rare type of B-cell non-Hodgkin lymphoma.
[Mustang Bio, Inc.] |
|
|
|
|
| September 19 – 20, 2022
Vejle, Denmark |
|
|
|
|
|
| | Philipps University of Marburg – Marburg, Germany |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | National University of Ireland Galway – Galway, Ireland |
|
|
|
| | Aarhus University – Aarhus, Denmark |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
